查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1928589

血管内旋转斑块动脉粥状硬化斑块切除术装置市场（按产品类型、技术、应用和最终用户划分），全球预测（2026-2032）

Endovascular Rotational Atherectomy Devices Market by Product Type, Technology, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年血管内旋转斑块动脉粥状硬化斑块切除术装置市值为 4.4121 亿美元，预计到 2026 年将成长至 4.7854 亿美元，预计到 2032 年将达到 6.8593 亿美元，复合年增长率为 6.50%。

关键市场统计数据
基准年 2025 4.4121亿美元
预计年份：2026年 4.7854亿美元
预测年份 2032 6.8593亿美元
复合年增长率 (%) 6.50%

简明扼要的行业概述，重点介绍临床驱动因素、设备发展历程以及影响旋切动脉粥状硬化斑块切除术技术应用的不断变化的生态系统。

血管内旋转动脉粥状硬化斑块切除术装置处于介入性心臟病学、週边血管治疗和医疗设备工程的关键交叉领域。这些装置是专门用于修復钙化病变并促进复杂动脉疾病患者成功再灌注的专用工具。可预测斑块修復的临床需求推动了装置形状、磨头几何形状和输送系统的迭代创新。如今，手术团队在选择动脉粥状硬化斑块切除术平台时会考虑疗效、安全性和工作流程整合。

推动血管专科领域旋切动脉粥状硬化斑块切除术治疗设备设计、临床工作流程和价值导向应用的关键变革性产业趋势

近年来，动脉粥状硬化斑块切除术装置的研发、评估和临床应用发生了变革性变化。首要变化是将术中影像和数据分析整合到决策流程中，使装置选择从主导直觉转向实证实践。这种整合正在改变装置的规格，临床医生更倾向于选择能够与血管内影像设备实现可预测整合且具有明确手术结束标准的系统。

评估不断变化的关税政策和贸易趋势对血管内器械价值链中製造、采购和策略决策的累积影响

关税的征收或贸易政策的调整将对设备的整个生命週期产生重大影响，涵盖采购、製造、定价和分销等各个环节。当金属零件、精密仪器或进口子系统的关税调整导致投入成本增加时，製造商面临一个迫在眉睫的选择：自行承担成本、调整标价或重组筹资策略。短期内，毛利率可能会受到压缩，促使製造商重新评估研发和生产扩张的资本配置。

将临床适应症、设备架构、临床环境和技术选择与商业化和开发路径联繫起来的策略性细分洞察

分析市场区隔的细微差别，可以揭示临床适应症、产品形式、临床环境和系统结构如何相互作用，从而指导产品开发和商业化策略。在分析应用领域时，冠状动脉疾病和周边动脉疾病之间的临床差异会直接影响器械的几何形状、钻头尺寸和介面相容性。在周边动脉疾病领域，颈动脉手术、透析通路维护和下肢动脉再灌注等特殊需求需要专门的方法，以最大限度地矫正病变，同时最大限度地降低栓塞风险。

美洲、欧洲、中东和非洲以及亚太市场临床应用、监管合规和商业化的区域趋势和策略方法

区域趋势对旋切动脉粥状硬化斑块切除术的临床实务模式、监管环境和商业策略有显着影响。在美洲，综合医疗网络和三级医疗中心的高手术量往往推动着手术创新，因此，那些拥有完善的培训项目、明确的报销标准和强大的本地服务体系的器械更受青睐。因此，面向该地区的製造商通常会强调真实世界的结果和协作培训计划，以加速器械在各种临床环境中的应用。

透过临床证据、一体化手术方案和稳健的供应链策略实现差异化竞争，从而确立医疗器材领先地位。

该领域的竞争发展更取决于企业如何建构临床证据、商业化和供应链韧性等能力，而非单纯的产品等效性。主要企业透过持续投资于临床证据的生成，并发表註册研究和实用性研究的结果来脱颖而出，这些研究能够证明手术在真实临床人群中的益处。同样重要的是，要建立健全的临床医生培训计划，以减少操作者的技术差异，并提高在临床诊疗现场对设备性能的评估能力。

医疗设备製造商可采取切实可行的策略行动，以扩大证据产生规模、完善商业模式并加强供应链和伙伴关係关係。

产业领导者应优先考虑一系列切实可行的倡议，以加强临床应用、提升商业性韧性并建立创新路径。首先，应投资于针对性的真实世界证据项目，以解决冠状动脉和周边血管领域具有重大影响的临床问题，并确保研究设计能够涵盖与临床医生、支付方和医院管理者相关的终点指标。同时，拓展结合模拟、指导和数位化学习的临床医生培训课程至关重要，这有助于减少操作差异，并加速在各种临床环境中自信地应用相关技术。

结合专家对话、临床文献综合、监管分析和检验的稳健混合方法研究确保了研究结果的可靠性。

这些研究结果所依据的研究方法结合了定性专家访谈和结构化的二次分析，以确保对临床和商业性动态进行平衡的解读。主要资料收集包括对介入性心臟病专家、血管专家、采购人员和监管顾问的深入访谈，以了解他们对器械性能、培训需求和采购行为的现场观点。此外，一个咨询小组也参与了这些访谈，以检验新出现的主题，并对不同医疗机构的流程进行细緻入微的解读。

临床、营运和商业性需求的整合将决定哪些公司能够在不断发展的心房和周边动脉动脉粥状硬化斑块切除术市场中获得持续优势。

血管内旋切动脉粥状硬化斑块切除术的市场环境呈现出快速的临床创新、不断发展的手术流程生态系统以及不断变化的商业性需求等特征。能够满足临床医生对可预测斑块修饰的需求、能够顺利融入手术流程并拥有严谨的真实世界证据支持的器械，预计在冠状动脉和外周血管疾病的治疗中都获得更高的普及率。同时，商业性成功将越来越依赖提供一体化解决方案、向购买者证明其经济价值以及在当前地缘政治和贸易不确定性下维持稳健的供应链的能力。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 依产品类型分類的血管内旋转动脉粥状硬化斑块切除术装置市场

  • 酒吧
  • 系统

9. 依技术分類的血管内旋转斑块动脉粥状硬化斑块切除术装置市场

  • 恆速系统
  • 变速系统

第十章 依应用分類的血管内旋转动脉粥状硬化斑块切除术装置市场

  • 冠状动脉疾病
  • 周边动脉疾病
    • 颈动脉
    • 透析通路
    • 下肢动脉

第十一章 依最终用户分類的血管内旋转动脉粥状硬化斑块切除术装置市场

  • 门诊手术中心
  • 心臟中心
  • 医院
    • 公立医院
    • 私立医院

12. 各地区血管内动脉粥状硬化斑块切除术装置市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 血管内旋转斑块动脉粥状硬化斑块切除术装置市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 各国血管内旋转斑块动脉粥状硬化斑块切除术装置市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

15. 美国血管内动脉粥状硬化斑块切除术装置市场

第十六章：中国血管内动脉粥状硬化斑块切除术装置市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • AngioDynamics, Inc.
  • Avinger, Inc.
  • B. Braun Melsungen AG
  • Becton, Dickinson and Company
  • Biotronik SE & Co. KG
  • Boston Scientific Corporation
  • Cardiovascular Systems, Inc.
  • Cook Medical LLC
  • Koninklijke Philips NV
  • Medtronic plc
  • Merit Medical Systems, Inc.
  • Penumbra, Inc.
  • Shockwave Medical, Inc.
  • Straub Medical AG
  • Terumo Corporation
Product Code: MRR-92740D85F051

The Endovascular Rotational Atherectomy Devices Market was valued at USD 441.21 million in 2025 and is projected to grow to USD 478.54 million in 2026, with a CAGR of 6.50%, reaching USD 685.93 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 441.21 million
Estimated Year [2026] USD 478.54 million
Forecast Year [2032] USD 685.93 million
CAGR (%) 6.50%

A concise industry overview highlighting clinical drivers, device evolution, and the shifting ecosystem that shapes adoption of rotational atherectomy technologies

Endovascular rotational atherectomy devices occupy a critical intersection of interventional cardiology, peripheral vascular therapies, and medical device engineering. These devices are specialized tools used to modify calcified lesions and facilitate successful revascularization in patients with complex arterial disease. The clinical imperative for predictable plaque modification has driven iterative innovation in device form factors, burr geometries, and delivery systems, and today procedural teams weigh efficacy, safety, and workflow integration when selecting an atherectomy platform.

Clinical adoption is shaped by several converging forces. Procedural volume growth for complex coronary and peripheral interventions, rising prevalence of vascular calcification in aging and comorbid populations, and a heightened focus on limb salvage pathways have combined to prioritize technologies that deliver consistent lesion debulking while minimizing distal embolization and procedural complications. Regulatory pathways and payer engagement continue to influence the speed of adoption, and multidisciplinary care teams increasingly evaluate device performance through the twin lenses of clinical outcomes and cost of care. Consequently, device manufacturers are investing in real-world evidence generation, training programs, and supply chain optimization to support sustained clinical uptake.

Looking ahead, the ecosystem around these devices is evolving beyond hardware alone. Adjunctive imaging, atherectomy-compatible guidewires and catheters, and procedural decision-support frameworks are emerging as complementary enablers. As a result, stakeholders across clinical, commercial, and regulatory domains are recalibrating their strategies to capture value from an integrated procedural model rather than a single-device sale. This trend elevates the importance of evidence-based positioning, user-centric training, and partnerships that bridge the gap between device performance in controlled studies and outcomes in routine clinical practice.

Key transformative industry trends driving device design, clinical workflows, and value-based adoption in rotational atherectomy care across vascular specialties

Recent years have seen transformative shifts that affect how rotational atherectomy devices are developed, evaluated, and adopted in clinical settings. The first major shift is the integration of procedural imaging and data analytics into the decision-making workflow, which moves device selection from intuition-driven to evidence-supported practice. This integration is altering device specifications, with clinicians favoring systems that offer predictable interactions with intravascular imaging modalities and clear procedural endpoints.

A second pivotal change is the movement toward modular procedural ecosystems rather than single-point solutions. Device vendors are expanding their value propositions to include training programs, bundled disposables, and service models that support operating room efficiency. Accordingly, hospitals and ambulatory centers increasingly prioritize total-procedure cost and throughput, prompting manufacturers to redesign packaging, sterilization logistics, and support services to fit different care settings.

Third, regulatory scrutiny and post-market surveillance have intensified, compelling companies to generate robust real-world evidence and to engage proactively with payers and health technology assessment bodies. This heightened oversight accelerates the adoption curve for devices that demonstrate consistent safety in heterogeneous patient populations. Finally, cross-disciplinary collaboration between peripheral and coronary intervention specialists is redefining procedural best practices, encouraging design innovations that cater to diverse lesion anatomies and access strategies. Taken together, these trends are reshaping competitive dynamics and elevating the importance of clinical, operational, and economic arguments in market positioning.

Assessing how evolving tariff policies and trade dynamics cumulatively influence manufacturing, sourcing, and strategic decisions across the endovascular device value chain

The imposition of tariffs and changes in trade policy can have material effects across the device lifecycle, from component sourcing and manufacturing to pricing and distribution. When tariff adjustments increase input costs on metallic components, precision instruments, or imported subsystems, manufacturers face immediate choices: absorb the cost, adjust list prices, or reconfigure sourcing strategies. In the short term this can compress gross margins and prompt reassessment of capital allocation for R&D and production scaling.

Over time, tariffs encourage supply chain localization and diversification. Device firms may accelerate investments in regional manufacturing hubs or qualify alternative suppliers to mitigate exposure to tariff volatility. Such shifts have implications for lead times, quality control, and inventory strategies, requiring tighter coordination between procurement, regulatory affairs, and quality systems. Clinicians and health systems may experience indirect impacts through procurement cycles and vendor contract negotiations as firms seek to preserve market access while protecting commercial viability.

A cumulative tariff effect also influences strategic partnerships and M&A dynamics. Companies looking to secure supply resilience or to gain localized manufacturing capabilities may pursue targeted acquisitions or joint ventures. In parallel, increased unit costs can amplify the importance of delivering demonstrable clinical benefits that justify price adjustments, reinforcing the imperative for rigorous outcomes data and payer engagement. Ultimately, tariff-driven cost pressures reshape competition by privileging firms with flexible manufacturing footprints, vertically integrated supply chains, and strong clinician and payer relationships that can absorb or justify price transitions.

Strategic segmentation insights that connect clinical indications, device architectures, care settings, and technological choices to commercialization and development pathways

A nuanced view of market segmentation illuminates how clinical indications, product form factors, care settings, and system architectures interact to guide development and commercialization strategies. When analyzing application areas, the clinical distinction between coronary artery disease and peripheral arterial disease has direct implications for device geometry, burr sizing, and interface compatibility; within peripheral arterial disease, specialized needs for carotid artery procedures, dialysis access maintenance, and lower limb artery revascularization demand tailored approaches to minimize embolic risk while maximizing lesion modification.

Product-type differentiation between burrs and systems informs a split strategy for companies that wish to support both consumable demand and capital equipment sales. Burr design innovations can be positioned as upgrades to existing capital platforms, while system-level innovation can create lock-in through proprietary interfaces and integrated disposables. End-user segmentation across ambulatory surgical centers, cardiac centers, and hospitals requires manufacturers to align training, service, and reimbursement support to the operational realities of each setting; within hospitals, the distinction between government and private institutions affects procurement cycles, contracting flexibility, and expectations for vendor-managed inventory.

Finally, technology segmentation between constant speed systems and variable speed systems highlights divergent performance philosophies: constant speed approaches prioritize procedural simplicity and predictability, whereas variable speed architectures emphasize adaptability to lesion morphology and operator preference. These technological choices cascade into clinician training requirements, maintenance schedules, and downstream accessories, and therefore they should inform product roadmaps and commercialization playbooks simultaneously rather than in isolation.

Regional dynamics and strategic approaches for clinical adoption, regulatory engagement, and commercialization across Americas, EMEA, and Asia-Pacific markets

Regional dynamics exert a powerful influence on clinical practice patterns, regulatory landscapes, and commercial strategies for rotational atherectomy devices. In the Americas, procedural innovation is often driven by integrated care networks and high procedural volumes in tertiary centers, which favor devices supported by robust training programs, reimbursement clarity, and local service infrastructure. Consequently, manufacturers targeting this region frequently emphasize real-world outcomes and collaborative training initiatives to accelerate adoption across diverse care settings.

In Europe, Middle East & Africa, heterogeneity across health systems requires flexible market entry strategies that balance centralized regulatory approvals with region-specific evidence generation and distribution models. Buyers in these regions may prioritize cost-effectiveness and long-term service agreements, and therefore suppliers must be prepared to demonstrate durable clinical benefit and offer adaptable commercial terms. In the Asia-Pacific region, rapid infrastructure investment, increasing procedural capacity, and growing emphasis on minimally invasive therapies create opportunities for both established and emerging players; success here often depends on local regulatory navigation, partnerships with regional distributors, and supply chain responsiveness to varying procurement cycles.

Across all regions, differences in physician training pathways, reimbursement frameworks, and hospital procurement processes mean that a one-size-fits-all approach is insufficient. Manufacturers that tailor their clinical education, value communication, and logistical support to regional needs while maintaining high standards for evidence generation and device quality will be best positioned to navigate the diverse regulatory and commercial terrains that characterize global markets.

Competitive differentiation driven by clinical evidence, integrated procedural solutions, and resilient supply chain strategies shaping leadership in the device landscape

Competitive dynamics in this sector are shaped less by pure product parity and more by how companies assemble capabilities across clinical evidence, commercialization, and supply resilience. Leading firms are differentiating through continuous investment in clinical evidence generation, publishing outcomes from registries and pragmatic studies that demonstrate procedural benefits across real-world cohorts. Equally important are robust clinician training programs that reduce variability in operator technique and thereby improve perceived device performance at the point of care.

From a commercial perspective, companies are enhancing value propositions by bundling capital systems with consumable burrs and by offering flexible purchasing models, including managed service agreements and outcome-linked contracts. Strategic partnerships with imaging providers and peripheral device makers are emerging as a way to create integrated procedural solutions that appeal to high-volume centers. On the manufacturing front, firms that have diversified supplier bases and multiple production sites demonstrate greater resilience to supply shocks, enabling steadier product availability and more predictable service timelines.

Intellectual property portfolios and regulatory track records remain important barriers to entry, but the competitive landscape also rewards nimble innovators who can rapidly translate clinical feedback into incremental device improvements. Finally, the ability to navigate complex reimbursement environments and to articulate a clear economic case for device adoption often separates successful commercial rollouts from stalled ones, underscoring the need for multidisciplinary alignment between clinical affairs, health economics, and sales operations.

Practical strategic actions for device makers to scale evidence generation, refine commercial models, and strengthen supply chain and partnership capabilities

Industry leaders should prioritize a set of actionable initiatives to strengthen clinical adoption, commercial resilience, and innovation pathways. First, invest in targeted real-world evidence programs that address high-impact clinical questions across coronary and peripheral indications, and ensure that study designs capture endpoints relevant to clinicians, payers, and hospital administrators. Complementary to this, expand clinician training programs that combine simulation, proctoring, and digital learning to reduce performance variability and to accelerate confident use in diverse care settings.

Second, re-evaluate commercial models to include bundled offerings, flexible procurement options, and service agreements that align with hospital and ambulatory center budgeting cycles. This approach can reduce friction at the point of purchase and support longer-term revenue predictability. Third, fortify supply chains by qualifying multiple suppliers for critical components, exploring regional manufacturing partnerships, and developing contingency inventory strategies to minimize disruption from trade policy shifts. Fourth, pursue interoperable device architectures and partnerships with imaging and accessory providers to create compelling integrated procedural ecosystems that enhance clinical workflow and differentiate product portfolios.

Finally, engage proactively with payers and health technology assessment bodies to build a transparent economic narrative that links device performance to reductions in complication rates, procedure times, or downstream interventions. Taken together, these actions will sharpen competitive positioning and enable companies to translate technical innovation into measurable clinical and commercial outcomes.

Robust mixed-methods research design combining expert engagement, clinical literature synthesis, regulatory analysis, and triangulation to ensure credible insights

The research approach underpinning these insights combines qualitative expert engagement with structured secondary analysis to ensure balanced interpretation of clinical and commercial dynamics. Primary data collection included in-depth interviews with interventional cardiologists, vascular specialists, procurement leaders, and regulatory consultants to capture frontline perspectives on device performance, training needs, and purchasing behaviors. These conversations were supplemented by advisory panels that validated emergent themes and provided nuanced interpretation of procedural workflows across care settings.

Secondary investigation encompassed peer-reviewed clinical literature, regulatory filings, device IFUs, and procedure registries to triangulate clinical claims and to understand device design evolution. In addition, analysis of procurement trends and hospital purchasing practices informed the commercial and regional insights. Data quality was reinforced through cross-validation methods, comparing clinician feedback against published outcomes and device labeling to identify consistent performance signals and potential gaps.

Throughout the process, methodological safeguards were applied to mitigate bias, including the use of independent expert reviewers and transparent documentation of data sources and analytical assumptions. This multilayered approach ensures that the conclusions reflect both the lived experience of clinical stakeholders and the documented technical and regulatory context that shapes device deployment.

Synthesis of clinical, operational, and commercial imperatives that determine which firms will secure sustainable advantage in the evolving atrial and peripheral atherectomy landscape

The landscape for endovascular rotational atherectomy devices is defined by rapid clinical innovation, evolving procedural ecosystems, and shifting commercial imperatives. Devices that align with clinician needs for predictable plaque modification, integrate smoothly into procedural workflows, and are supported by rigorous real-world evidence will command greater consideration in both coronary and peripheral indications. At the same time, commercial success will increasingly depend on the ability to offer integrated solutions, to demonstrate economic value to purchasers, and to maintain resilient supply chains in the face of geopolitical and trade uncertainties.

Stakeholders that proactively invest in clinician education, evidence generation, and flexible commercialization models will be better positioned to convert technical differentiation into durable market advantage. Likewise, regional sensitivity in regulatory engagement and distribution strategy will be essential for expanding global reach without compromising compliance or service quality. In summary, the convergence of clinical, operational, and economic drivers creates both challenges and opportunities for device makers; those that execute with strategic clarity and operational rigor will capture disproportionate value as the sector continues to mature.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Endovascular Rotational Atherectomy Devices Market, by Product Type

  • 8.1. Burrs
  • 8.2. Systems

9. Endovascular Rotational Atherectomy Devices Market, by Technology

  • 9.1. Constant Speed System
  • 9.2. Variable Speed System

10. Endovascular Rotational Atherectomy Devices Market, by Application

  • 10.1. Coronary Artery Disease
  • 10.2. Peripheral Arterial Disease
    • 10.2.1. Carotid Artery
    • 10.2.2. Dialysis Access
    • 10.2.3. Lower Limb Artery

11. Endovascular Rotational Atherectomy Devices Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Cardiac Centers
  • 11.3. Hospitals
    • 11.3.1. Government Hospitals
    • 11.3.2. Private Hospitals

12. Endovascular Rotational Atherectomy Devices Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Endovascular Rotational Atherectomy Devices Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Endovascular Rotational Atherectomy Devices Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Endovascular Rotational Atherectomy Devices Market

16. China Endovascular Rotational Atherectomy Devices Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. AngioDynamics, Inc.
  • 17.7. Avinger, Inc.
  • 17.8. B. Braun Melsungen AG
  • 17.9. Becton, Dickinson and Company
  • 17.10. Biotronik SE & Co. KG
  • 17.11. Boston Scientific Corporation
  • 17.12. Cardiovascular Systems, Inc.
  • 17.13. Cook Medical LLC
  • 17.14. Koninklijke Philips N.V.
  • 17.15. Medtronic plc
  • 17.16. Merit Medical Systems, Inc.
  • 17.17. Penumbra, Inc.
  • 17.18. Shockwave Medical, Inc.
  • 17.19. Straub Medical AG
  • 17.20. Terumo Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY BURRS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY BURRS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY BURRS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY CONSTANT SPEED SYSTEM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY CONSTANT SPEED SYSTEM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY CONSTANT SPEED SYSTEM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY VARIABLE SPEED SYSTEM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY VARIABLE SPEED SYSTEM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY VARIABLE SPEED SYSTEM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY CORONARY ARTERY DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY CORONARY ARTERY DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY CORONARY ARTERY DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY CAROTID ARTERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY CAROTID ARTERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY CAROTID ARTERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY DIALYSIS ACCESS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY DIALYSIS ACCESS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY DIALYSIS ACCESS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY LOWER LIMB ARTERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY LOWER LIMB ARTERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY LOWER LIMB ARTERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY CARDIAC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY CARDIAC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY CARDIAC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY GOVERNMENT HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY GOVERNMENT HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY GOVERNMENT HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. AMERICAS ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 52. AMERICAS ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 53. AMERICAS ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 54. AMERICAS ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 55. AMERICAS ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 56. AMERICAS ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 57. AMERICAS ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 58. NORTH AMERICA ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. NORTH AMERICA ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 60. NORTH AMERICA ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 62. NORTH AMERICA ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 65. LATIN AMERICA ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. LATIN AMERICA ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. LATIN AMERICA ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 68. LATIN AMERICA ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 69. LATIN AMERICA ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 70. LATIN AMERICA ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE, MIDDLE EAST & AFRICA ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE, MIDDLE EAST & AFRICA ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE, MIDDLE EAST & AFRICA ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE, MIDDLE EAST & AFRICA ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 86. MIDDLE EAST ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. MIDDLE EAST ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. MIDDLE EAST ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 90. MIDDLE EAST ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 91. MIDDLE EAST ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. MIDDLE EAST ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 93. AFRICA ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. AFRICA ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. AFRICA ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 96. AFRICA ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 97. AFRICA ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 98. AFRICA ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. AFRICA ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. ASEAN ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. ASEAN ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. ASEAN ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 111. ASEAN ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 112. ASEAN ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 113. ASEAN ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. ASEAN ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 115. GCC ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GCC ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. GCC ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 118. GCC ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 119. GCC ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 120. GCC ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. GCC ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPEAN UNION ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPEAN UNION ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPEAN UNION ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPEAN UNION ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPEAN UNION ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPEAN UNION ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPEAN UNION ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 129. BRICS ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. BRICS ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. BRICS ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 132. BRICS ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 133. BRICS ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 134. BRICS ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. BRICS ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 136. G7 ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. G7 ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. G7 ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 139. G7 ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 140. G7 ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 141. G7 ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. G7 ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 143. NATO ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. NATO ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. NATO ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 146. NATO ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 147. NATO ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 148. NATO ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. NATO ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. UNITED STATES ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 152. UNITED STATES ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. UNITED STATES ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 154. UNITED STATES ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 155. UNITED STATES ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 156. UNITED STATES ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. UNITED STATES ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 158. CHINA ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 159. CHINA ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. CHINA ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 161. CHINA ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 162. CHINA ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 163. CHINA ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. CHINA ENDOVASCULAR ROTATIONAL ATHERECTOMY DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)